From Nasdaq: 2025-05-09 18:26:00

Acadia Pharmaceuticals (ACAD) reported quarterly earnings of $0.11 per share, surpassing expectations of $0.10 per share, with a 10% earnings surprise. Revenues were $244.32 million, beating estimates by 1.23%. The stock has underperformed the market, with a 20.8% decline this year. Analysts are closely watching the company’s earnings outlook for future performance.

In the same industry, Adherex Technologies Inc. (FENC) is expected to report a quarterly loss of $0.12 per share, down 129.3% year-over-year, with revenues expected to be $8.01 million, a 68.5% decrease from the previous year. Investors are advised to monitor industry trends and earnings estimate revisions for both companies.

For potential investors, there are mixed estimates for Acadia Pharmaceuticals Inc. (ACAD), which currently holds a Zacks Rank #3 (Hold). Analysts are predicting an EPS of $0.18 for the next quarter and $0.68 for the current fiscal year. Industry performance can also impact stock performance, with the Medical – Biomedical and Genetics industry currently in the top 35% of Zacks industries.



Read more at Nasdaq: Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)